You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Nimotuzumab

Showing 1 - 25 of 114
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cervical Cancer Trial (Nimotuzumab?Tislelizumab)

Not yet recruiting
  • Cervical Cancer
  • (no location specified)
Sep 9, 2023

Solid Tumor, EGFR Amplification Trial in Tianjin (Nimotuzumab)

Recruiting
  • Solid Tumor
  • EGFR Amplification
  • Nimotuzumab
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Aug 28, 2023

Gastric or Esophagogastric Junction Adenocarcinoma Trial (nimotuzumab plus paclitaxel, plus paclitaxel)

Not yet recruiting
  • Gastric or Esophagogastric Junction Adenocarcinoma
  • nimotuzumab plus paclitaxel
  • placebo plus paclitaxel
  • (no location specified)
Aug 3, 2023

Esophageal Carcinoma Trial in Nanjing (Nimotuzumab, Tigio, Concurrent radiation therapy)

Enrolling by invitation
  • Esophageal Carcinoma
  • Nimotuzumab
  • +2 more
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital of Nanjing Medical University
Sep 19, 2023

Nasopharyngeal Carcinoma Trial in Xi'an (gemcitabine,nimotuzumab, toripalimab, gemcitabine, cisplatin)

Recruiting
  • Nasopharyngeal Carcinoma
  • gemcitabine,nimotuzumab, toripalimab
  • gemcitabine, cisplatin
  • Xi'an, Shaanxi, China
    Department of Radiation Oncology, Xijing Hospital, Fourth Milita
Sep 5, 2023

Cervical Cancer Trial in Xi'an (Caldonirimab and Nimotuzumab)

Active, not recruiting
  • Cervical Cancer
  • Caldonirimab and Nimotuzumab
  • Xi'an, Shaanxi, China
    The First Affiliated Hospital of Xi'an Jiao Tong University
Oct 31, 2022

Nasopharyngeal Carcinoma, Nasopharyngeal Tumors, Nasopharyngeal Diseases Trial in Guangzhou (Nimotuzumab, Cisplatin)

Recruiting
  • Nasopharyngeal Carcinoma
  • +3 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Nov 3, 2022

Oral Squamous Cell Carcinoma Trial in Beijing (Toripalimab)

Not yet recruiting
  • Oral Squamous Cell Carcinoma
  • Beijing, China
    Peking Union Medical College Hospital, Chinese Academy of Medica
Apr 5, 2023

Lung Cancer, Colorectal Cancer Trial in Saskatoon (50 mg 89Zr-DFO-Nimotuzumab, 1 mg 89Zr-DFO-Nimotuzumab)

Recruiting
  • Lung Cancer
  • Colorectal Cancer
  • 50 mg 89Zr-DFO-Nimotuzumab
  • 1 mg 89Zr-DFO-Nimotuzumab
  • Saskatoon, Saskatchewan, Canada
    Royal University Hospital
May 18, 2022

Head and Neck Squamous Cell Carcinoma Trial (Nimotuzumab Combined With Neoadjuvant Chemotherapy)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Nimotuzumab Combined With Neoadjuvant Chemotherapy
  • (no location specified)
Jun 29, 2022

Penile Cancer Trial in Guangzhou (Albumin-Bound Paclitaxel, Ifosfamide, Cisplatin)

Completed
  • Penile Cancer
  • Albumin-Bound Paclitaxel
  • +4 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jun 8, 2022

Nasopharyngeal Carcinoma Trial in Shanghai (Camrelizumab, Nimotuzumab, neoadjuvant chemo and CCRT)

Recruiting
  • Nasopharyngeal Carcinoma
  • Shanghai, Shanghai, China
    Fudan Universtiy Shanghai Cancer Centre
Mar 6, 2023

Pancreatic Neuroendocrine Tumor Trial in Shanghai (Nimotuzumab)

Not yet recruiting
  • Pancreatic Neuroendocrine Neoplasm
  • Nimotuzumab
  • Shanghai, Shanghai, China
    Department of Pancreatic Surgery, Fudan University Shanghai Canc
Apr 4, 2022

Colorectal Cancer Trial in Nanjing, Beijing (Nimotuzumab, Irinotecan)

Completed
  • Colorectal Cancer
  • Nanjing, Jiangsu, China
  • +1 more
Mar 3, 2022

Toxicity, Drug Trial in Hefei (neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery)

Recruiting
  • Toxicity, Drug
  • neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery
  • Hefei, Anhui, China
    Anhui Provicial Hospital
May 1, 2022

Nasopharyngeal Carcinoma by AJCC V8 Stage Trial in China (Nimotuzumab, Gemcitabine, Cisplatin)

Recruiting
  • Nasopharyngeal Carcinoma by AJCC V8 Stage
  • Nimotuzumab
  • +3 more
  • Baise, Guangxi, China
  • +8 more
Jan 29, 2023

Esophageal Trial in China (Nimotuzumab, Radiotherapy)

Completed
  • Esophageal
  • Nimotuzumab
  • Radiotherapy
  • Harbin, Heilongjiang, China
  • +4 more
Mar 3, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (CCRT+Nimotuzumab, CCRT alone)

Active, not recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen Universitty Cancer Center
Nov 22, 2021

Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN

Recruiting
  • Locally Advanced Head and Neck Squamous Cell Carcinoma
  • nimotuzumab
  • Beijing, Beijing, China
  • +4 more
Mar 3, 2022

Esophageal Cancer, Chemoradiotherapy, Nimotuzumab Trial in Beijing (Radiotherapy, Nimotuzumab, S-1)

Recruiting
  • Esophageal Cancer
  • +3 more
  • Radiotherapy
  • +2 more
  • Beijing, China
    Department of Radiation Oncology, National Cancer Center/Nationa
Oct 21, 2021

Nasopharyngeal Carcinoma Trial in Guangzhou (RT plus Nimotuzumab, RT plus Cisplatin)

Recruiting
  • Nasopharyngeal Carcinoma
  • RT plus Nimotuzumab
  • RT plus Cisplatin
  • Guangzhou, Guangdong, China
    Sun Yat-sen Universitty Cancer Center
Nov 3, 2021

Oral Squamous Cell Carcinoma Trial in Yichang (Nimotuzumab, Docetaxel, Carboplatin)

Recruiting
  • Oral Squamous Cell Carcinoma
  • Nimotuzumab
  • +2 more
  • Yichang, Hubei, China
    Department of Medical Oncology, Central Hospital of Yichang City
Nov 5, 2021

Cervical Squamous Cell Carcinoma Trial in Beijing (Nimotuzumab, EBRT combined with brachytherapy)

Not yet recruiting
  • Cervical Squamous Cell Carcinoma
  • Nimotuzumab
  • EBRT combined with brachytherapy
  • Beijing, Beijing, China
    Peking University 3rd Hospital
Jul 21, 2021

Esophageal Squamous Cell Carcinoma Trial in Zhengzhou (Nimotuzumab + SHR-1210)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Nimotuzumab + SHR-1210
  • Zhengzhou, Henan, China
    The First Affiliated Hospital of Zhengzhou University
Jul 6, 2021

Head and Neck Squamous Cell Carcinoma Trial in China (Nimotuzumab)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Nimotuzumab
  • Hangzhou, China
  • +5 more
Aug 20, 2021